Irene Wapnir, MD from Stanford University School of Medicine speaks about SABCS Abstract OT1-09-01 A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS).
Link to Trial:
https://clinicaltrials.gov/ct2/show/NCT03909282
Introduction:
In individuals with ductal carcinoma in situ, lumpectomy plus breast radiation (RT) provide satisfactory long-term disease management (DCIS). These therapies were found to prevent invasive ipsilateral breast tumor recurrences by 52 percent when compared to lumpectomy alone in a combined analysis of the NSABP B17/24 trials. Because RT has been used as an adjuvant to surgery for so long, nothing is known about its effects on DCIS that is still intact or untreated. Understanding the efficacy of radiation therapy may aid in optimizing DCIS treatment and avoiding overtreatment.
Design of the Trial:
The goal of the ongoing phase 2 pilot randomized trial is to see if neoadjuvant RT (neoRT) has any ablative or therapeutic effects on pure DCIS. On core needle biopsy (CNB), DCIS was diagnosed, and a second wireless marker was placed as a fiducial.